516526-44-6

Basic information

• Product Name: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6,7-dimethoxy-
• CAS NO: 516526-44-6
• Molecular Formula: C17H13FN2O5
• Molecular Weight: 344.299
• Mol File: 516526-44-6.mol
• Article Data: 26

Chemical Properties

• CAS DataBase Reference: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6,7-dimethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6,7-dimethoxy-(516526-44-6)
• EPA Substance Registry System: Quinoline, 4-(2-fluoro-4-nitrophenoxy)-6,7-dimethoxy-(516526-44-6)

Safety Data

• Hazardous Substances Data: 516526-44-6(Hazardous Substances Data)

Upstream product

• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 403-19-0 2-fluoro-4-nitrophenol 
• 4101-30-8 2-amino-4,5-dimethoxyacetophenone 
• 127285-54-5 1,4-dihydro-6,7-dimethoxy-4-oxoquinoline 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 
• 369-34-6 3,4-difluoronitrobenzene 
• 6315-89-5 3,4-dimethoxyaniline 
• 213699-53-7 5-(((3,4-dimethoxyphenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 4101-32-0 4',5'-dimethoxy-2'-nitroacetophenone 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 
• 61324-40-1 3-benzyloxy-4-methoxybenzeneamine 
• 205448-29-9 7-benzyloxy-4-hydroxy-6-methoxyquinoline 
• 636-93-1 5-nitroguaiacol 

Downstream Products

• 347161-74-4 4-[(6,7-dimethoxyquinolin-4-yl)oxy]-3-fluoroaniline 
• 479690-08-9 1-(2-fluoro-4-nitrophenyl)-6-hydroxy-7-methoxy-quinoline 
• 516526-45-7 4-(2-fluoro-4-nitrophenoxy)-7-methoxylquinolyl-6-ol 
• 1361031-15-3 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-1,5-dimethyl-pyrazole-3-carboxamide trifluoroacetate 
• 1361030-42-3 N-[4-[(6,7-dimethoxy-4-quinolyl)oxy]-3-fluoro-phenyl]-4-ethoxy-1-(4-fluorophenyl)pyrazole-3-carboxamide 
• 1361030-62-7 N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-(2-(dimethylamino)ethyl)-1-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 
• 1192298-98-8 N-[4-(6,7-dimethoxyquinolin-4-yloxy)-3-fluorophenyl]-2-trifluoromethylbenzenesulfonamide 

Relevant articles and documents

Design, Synthesis and Biological Evaluation of Novel α-Acyloxycarboxamide-Based Derivatives as c-Met Inhibitors

Dysregulated HGF/c-Met signalling has been associated with many human cancers, poor clinical outcomes, and even resistance acquisition to some approved targeted therapies. As such, c-Met kinase has emerged as an attractive target for anticancer drug discovery. Herein, a series of 6,7-disubstitued-4-(2-fluorophenoxy)quinoline derivatives bearing α-acyloxycarboxamide moiety were designed, synthesized via Passerini reaction as the key step, and evaluated for their in vitro biological activities against c-Met kinase and five selected cancer cell lines. The preliminary structure-activity relationship demonstrated that α-acyloxycarboxamide as the 5-atom linker maintained the potent antitumor potency. Among these compounds, compound 25s (c-Met IC50 = 4.06 nmol/L) was identified as the most promising lead compound and displayed the most potent antiproliferative activities against A549, HT-29 and MDA-MB-231 cell lines with IC50 of 0.39, 0.20, and 0.58 μmol/L, which were 1.3-, 1.4- and 1.2-fold superior to foretinib, respectively. The further studies indicated that compound 25s can induce apoptosis of A549 cells and arrest efficiently the cell cycle distribution in G2/M phase of A549 cells. Moreover, compound 25s can also inhibit c-Met phosphorylation in A549 cells by a dose-dependent manner. Collectively, these results indicated that compound 25s could be a potential anticancer lead compound deserving for further development.

MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF

The present invention relates to multi-substituted pyridone derivatives and therapeutic use thereof. In particular, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, as well as use thereof as a tyrosine kinase inhibitor, in particular, use thereof in treating a disease associated with tyrosine kinase activity. Each substituent in the formula (I) is defined as in the specification.

PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.